Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs
Queen Mary University of London
25,000 participants
Nov 1, 2021
OBSERVATIONAL
Conditions
Summary
We will determine how best to manage the hepatitis C virus (HCV) epidemic in Pakistan by measuring effectiveness of Pakistan-government sponsored current therapies, emergence of viral resistance, consequences of infection (chiefly liver cancer) and through developing models, based on incidence data, determine the proportion of people who need curative treatment to eliminate HCV, and assess whether targeting can optimise this.
Eligibility
Inclusion Criteria5
- Adults over 18yrs old
- Willing to undergo hepatitis C testing
- Able and willing to give informed consent
- Willing to return in 12 months time for repeat testing
- Resident in area and not planning to leave the region
Exclusion Criteria4
- Unwilling to give consent
- Unwilling or unable to undergo the necessary procedures
- Clinically significant illness (other than HCV) or other major medical condition that may interfere with the subject's treatment, assessment or compliance with protocol.
- Co-morbidities limiting life expectancy to less than 12 months
Interventions
We will test HCV positive patients after treatment to observe if they achieve SVR
HCV antibody test used to establish if patients have had or are actively infected with HCV
AST/ALT and platelets to determine APRI score
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04943588